TM stands for trademark, not my initials...

Final CNIPA Measures for Administrative Adjudication of Major Patent Infringement Disputes Announced on 26 May 2021

Major points, in my view, are as below: Article 8 - setting up of a workstation at the exhibition to handle IP infringement complaints, which is staffed with law enforcement personnel...

Suggestion to introduce use requirement in trademark applications in the reply to no. 1702 suggestion from the National People's Congress

In the US, the Orange Book is a publication from the US FDA that identifies drug products with marketing approval from the FDA and related patent and exclusivity information.

This is the October 2021 version of this guide, as there have been many developments shortly after my first July version was finished on 19 July 2021.

CN Supreme Court announced that defendant could claim from plaintiff in abusive litigation yesterday on 3 June 2021.

The Cyberspace Administration of China announced Methods for Identifying Synthetic Content Generated by Artificial Intelligence on 7 March 2025.

For patents (invention patent, utility model, and design), ONLY grant numbers are reported.

These guidelines were announced by the CNIPA on 29 December 2023 at the link below.

It is my honor to have my article on this published by the October 202 issue of UK CIPA Journal.

Yet another two CN IP updates – SPC updates its stipulations on handling IP cases, and CNIPA proposed measures to evaluate creditability of trademark agencies/agents.

This complaint is in reaction to the China's Supreme People's Court decision in Aug 2020 in Huawei v. Conversant.

The attached English version of the SPC IP Court annual report is from Fan Li of CCPIT.

This report of 226 pages is available at https://www.gov.cn/lianbo/bumen/202306/P020230612294618624831.pdf

Thanks for the heads up from Aaron Wininger of Schwegman Lundberg & Woessner, the first drug patent linkage decision has been decided by the Beijing IP Court.

This was published yesterday on 26 October 2021 at the link above, at which the Chinese draft regulations is available.

Sunitinib is a drug for treating cancers in the stomach, intestine, kidney and pancreas, marketed by Pfizer under the name Sutent.

On 4 November 2024, the China State Administration for Market Regulation (SAMR) announced the finalized "Anti-monopoly guidelines for standard essential patents" (the guidelines) at the link below:

Many of you may know I work from home in Hong Kong most of the time, while most of my colleagues (200+) are in Beijing. During this pandemic, I have done so since 23 January, right...